BTIG Maintains Buy on MDxHealth, Lowers Price Target to $4
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $7 to $4.
BTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $7 to $4.